23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › KRYSTAL BIOTECH INC. › 2023-2024

KRYSTAL BIOTECH INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and KRYSTAL BIOTECH INC.’s Form 8-K, filed May 21, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 256Asset managers, any item
  • 1,751Fund votes
  • May 17, 2024Meeting date

Results at a glance

Meeting of May 17, 2024: 5 items on KRYSTAL BIOTECH INC.’s Form 8-K, filed May 21, 2024: 2 approved · 3 passed (calculated).

Dissent

Significant dissent: 1 director (23.6% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore KRYSTAL BIOTECH INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by KRYSTAL BIOTECH INC.

These tallies are KRYSTAL BIOTECH INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 21, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

KRYSTAL BIOTECH INC. — official shareholder meeting results, meeting held May 17, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Suma M. Krishnan 21,058,004---- 1,498,0172,244,047 93%Passed (calculated)—
Elect Director: Julian S. Gangolli 17,226,067---- 5,329,9542,244,047 76%Passed (calculated)—
Elect Director: Catherine Mazzacco 20,382,924---- 2,173,0972,244,047 90%Passed (calculated)—
2. Ratification of Appointment of Independent Registered Public Accounting Firm 24,769,8387,43822,792 ---- 99.9%Approved—
3. Non-Binding, Advisory Vote on Named Executive Officer Compensation 21,697,311851,6907,020 --2,244,047 96%Approved—

This meeting is also recorded here as May 21, 2024; both records come from the same filing, so the date should be checked against it.

Source: KRYSTAL BIOTECH INC., Form 8-K, filed with the SEC on May 21, 2024 — read the filing on EDGAR.

How asset managers voted at the KRYSTAL BIOTECH INC. 2023-2024 meeting

256 asset managers disclosed a vote on at least one KRYSTAL BIOTECH INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Catherine Mazzacco

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 20,382,924WITHHELD: 2,173,097
Details: description as filed, official tally, votes by 85 asset managers

Description as filed by funds: Election of Class I Directors: Catherine Mazzacco

KRYSTAL BIOTECH INC.’s own tally for this item (“Elect Director: Catherine Mazzacco”): 20,382,924 for, 2,173,097 withheld, per its Form 8-K filed May 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 9,625,171 for, 14 against, 958,894 withheld, 95,219 abstained.

FOR
FOR: 9,625,171AGAINST: 14ABSTAIN: 95,219WITHHOLD: 958,894
Largest asset managers voting on “Election of Class I Directors: Catherine Mazzacco” at KRYSTAL BIOTECH INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity3,613,9880 00For
Vanguard2,370,2000 00For
T. Rowe Price531,8540 00For
BlackRock496,0280 00For
Dimensional00 0468,691Withhold
State Street462,0850 0626For
Lord Abbett347,3420 00For
Prudential/PGIM342,2730 02,414For
Manager Directed Portfolios246,1940 00For
TIAA242,5160 00For
Charles Schwab188,7780 00For
MUTUAL FUND SERIES TRUST136,4850 00For
Victory Capital00 088,375Withhold
TimesSquare Capital Management, LLC84,8410 00For
Equitable47,7700 023,260Mixed
Goldman Sachs00 067,089Withhold
Franklin Custodian Funds60,0000 00For
Nuveen56,5230 00For
Putnam51,0450 00For
John Hancock36,2810 8,0330Mixed
Columbia Threadneedle43,6920 00For
Bridge Builder Trust3,9340 39,1200Mixed
Jackson National00 40,3160Abstain
Allspring00 039,102Withhold
Aberdeen00 039,024Withhold

Showing the 25 largest of 85 asset managers. All 85 are in the interactive database (link above).

Elect Director: Julian S. Gangolli

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%WITHHELD
FOR: 17,226,067WITHHELD: 5,329,954
Details: description as filed, official tally, votes by 85 asset managers

Description as filed by funds: Election of Class I Directors: Julian S. Gangolli

KRYSTAL BIOTECH INC.’s own tally for this item (“Elect Director: Julian S. Gangolli”): 17,226,067 for, 5,329,954 withheld, per its Form 8-K filed May 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 8,907,811 for, 14 against, 1,651,657 withheld, 119,816 abstained.

FORWITHHOLD
FOR: 8,907,811AGAINST: 14ABSTAIN: 119,816WITHHOLD: 1,651,657
Largest asset managers voting on “Election of Class I Directors: Julian S. Gangolli” at KRYSTAL BIOTECH INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity3,613,9880 00For
Vanguard2,370,2000 00For
T. Rowe Price531,8540 00For
BlackRock496,0280 00For
Dimensional00 0468,691Withhold
State Street4600 0462,251Withhold
Lord Abbett347,3420 00For
Prudential/PGIM342,2730 02,414For
Manager Directed Portfolios246,1940 00For
TIAA242,5160 00For
Charles Schwab188,7780 00For
MUTUAL FUND SERIES TRUST136,4850 00For
Victory Capital00 088,375Withhold
TimesSquare Capital Management, LLC84,8410 00For
Equitable47,7700 023,260Mixed
Goldman Sachs00 067,089Withhold
Franklin Custodian Funds00 060,000Withhold
Nuveen56,5230 00For
Putnam51,0450 00For
John Hancock36,2810 8,0330Mixed
Columbia Threadneedle00 043,692Withhold
Bridge Builder Trust3,9340 39,1200Mixed
Jackson National00 40,3160Abstain
Allspring00 039,102Withhold
Aberdeen00 039,024Withhold

Showing the 25 largest of 85 asset managers. All 85 are in the interactive database (link above).

Elect Director: Suma M. Krishnan

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 21,058,004WITHHELD: 1,498,017
Details: description as filed, official tally, votes by 85 asset managers

Description as filed by funds: Election of Class I Directors: Suma M. Krishnan

KRYSTAL BIOTECH INC.’s own tally for this item (“Elect Director: Suma M. Krishnan”): 21,058,004 for, 1,498,017 withheld, per its Form 8-K filed May 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 85 asset managers below reported 9,690,504 for, 980,014 withheld, 8,780 abstained.

FOR
FOR: 9,690,504ABSTAIN: 8,780WITHHOLD: 980,014
Largest asset managers voting on “Election of Class I Directors: Suma M. Krishnan” at KRYSTAL BIOTECH INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity3,613,9880 00For
Vanguard2,370,2000 00For
T. Rowe Price531,8540 00For
BlackRock496,0280 00For
Dimensional00 0468,691Withhold
State Street1,0330 0461,678Withhold
Lord Abbett347,3420 00For
Prudential/PGIM344,6870 00For
Manager Directed Portfolios246,1940 00For
TIAA242,5160 00For
Charles Schwab188,7780 00For
MUTUAL FUND SERIES TRUST136,4850 00For
Victory Capital88,3750 00For
TimesSquare Capital Management, LLC84,8410 00For
Equitable47,7700 023,260Mixed
Goldman Sachs67,0890 00For
Franklin Custodian Funds60,0000 00For
Nuveen56,5230 00For
Putnam51,0450 00For
John Hancock44,3140 00For
Columbia Threadneedle43,6920 00For
Bridge Builder Trust43,0540 00For
Jackson National34,1410 6,1750Mixed
Allspring39,1020 00For
Aberdeen39,0240 00For

Showing the 25 largest of 85 asset managers. All 85 are in the interactive database (link above).

Non-Binding, Advisory Vote on Named Executive Officer Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 16 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 21,697,311AGAINST: 851,690
Details: description as filed, official tally, votes by 256 asset managers

Description as filed by funds: APPROVAL OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, ON A NON-BINDING, ADVISORY BASIS.

KRYSTAL BIOTECH INC.’s own tally for this item (“3. Non-Binding, Advisory Vote on Named Executive Officer Compensation”): 21,697,311 for, 851,690 against — passed, per its Form 8-K filed May 21, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Three: Non-Binding, Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers for the fiscal year ended December 31, 2023, as disclosed in the Company's proxy sta…”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 84 asset managers voting on “APPROVAL OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, ON A NON-BINDING, ADVISORY BASIS.” at KRYSTAL BIOTECH INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity3,613,9880 00For
Vanguard2,370,2000 00For
T. Rowe Price531,8540 00For
BlackRock496,0280 00For
Dimensional468,6910 00For
State Street462,7110 00For
Lord Abbett347,3420 00For
Prudential/PGIM344,6870 00For
Manager Directed Portfolios246,1940 00For
TIAA242,5160 00For
Charles Schwab188,7780 00For
MUTUAL FUND SERIES TRUST136,4850 00For
Victory Capital88,3750 00For
Equitable71,0300 00For
Goldman Sachs67,0890 00For
Franklin Custodian Funds60,0000 00For
Nuveen56,5230 00For
Putnam51,0450 00For
John Hancock44,3140 00For
Columbia Threadneedle43,6920 00For
Bridge Builder Trust43,0540 00For
Jackson National40,3160 00For
Allspring39,1020 00For
Aberdeen039,024 00Against
QUANTITATIVE MASTER SERIES LLC38,1590 00For

Fund voting reports, all 84 managers: 10,537,576 for, 39,634 against, 2,820 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 194 asset managers voting on “APPROVAL OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, ON A NON-BINDING, ADVISORY BASIS.” at KRYSTAL BIOTECH INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity4,243,3260 00For
Redmile Group, LLC1,508,2500 00For
State Street886,1590 00For
T. Rowe Price655,7370 00For
JENNISON ASSOCIATES LLC587,6961,364 00For
BlackRock539,0550 00For
GEODE CAPITAL MANAGEMENT, LLC497,2830 00For
Hood River Capital Management LLC463,1420 00For
LORD, ABBETT & CO. LLC425,3630 00For
Nuveen324,5780 00For
UBS0265,652 00Against
Woodline Partners LP252,5260 00For
SEB Investment Management AB0244,061 00Against
Charles Schwab188,8000 00For
Northern Trust180,91215 00For
JPMorgan168,6980 00For
Victory Capital158,0220 00For
Man Group plc0157,550 00Against
C WorldWide Asset Management Fondsmaeglerselskab A/S0135,809 00Against
PICTET ASSET MANAGEMENT SA111,0980 00For
Rock Springs Capital Management LP100,7730 00For
MELLON INVESTMENTS Corp90,4000 00For
S Squared Technology, LLC90,2150 00For
Vestal Point Capital, LP85,9790 00For
TimesSquare Capital Management, LLC84,8410 00For

Institutional-manager reports, all 194 managers: 13,135,435 for, 960,407 against, 326 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 24,769,838AGAINST: 7,438
Details: description as filed, official tally, votes by 89 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2024.

KRYSTAL BIOTECH INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 24,769,838 for, 7,438 against — passed, per its Form 8-K filed May 21, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 10,680,571 for, 81 against, 2,820 abstained.

FOR
FOR: 10,680,571AGAINST: 81ABSTAIN: 2,820
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR” at KRYSTAL BIOTECH INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity3,613,9880 00For
Vanguard2,370,2000 00For
T. Rowe Price531,8540 00For
BlackRock496,0280 00For
Dimensional468,6910 00For
State Street462,7110 00For
Lord Abbett347,3420 00For
Prudential/PGIM344,6870 00For
Manager Directed Portfolios246,1940 00For
TIAA242,5160 00For
Charles Schwab188,7780 00For
MUTUAL FUND SERIES TRUST136,4850 00For
Victory Capital88,3750 00For
TimesSquare Capital Management, LLC84,8410 00For
Equitable71,0300 00For
Goldman Sachs67,0890 00For
Franklin Custodian Funds60,0000 00For
Nuveen56,5230 00For
Putnam51,0450 00For
John Hancock44,3140 00For
Columbia Threadneedle43,6920 00For
Bridge Builder Trust43,0540 00For
Jackson National40,3160 00For
Allspring39,1020 00For
Aberdeen39,0240 00For

Showing the 25 largest of 89 asset managers. All 89 are in the interactive database (link above).

Largest KRYSTAL BIOTECH INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 28,528,000 shares outstanding at the time of that meeting.

Fund voting reports: top KRYSTAL BIOTECH INC. shareholders by shares voted on “APPROVAL OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, ON A NON-BINDING…”, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 12.67%
2Vanguard 8.31%
3T. Rowe Price 1.86%
4BlackRock 1.74%
5Dimensional 1.64%
6State Street 1.62%
7Lord Abbett 1.22%
8Prudential/PGIM 1.21%
9Manager Directed Portfolios 0.86%
10TIAA 0.85%
Institutional-manager reports: top KRYSTAL BIOTECH INC. shareholders by shares voted on “APPROVAL OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, ON A NON-BINDING…”, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 14.87%
2Redmile Group, LLC 5.29%
3State Street 3.11%
4T. Rowe Price 2.30%
5JENNISON ASSOCIATES LLC 2.06%
6BlackRock 1.89%
7GEODE CAPITAL MANAGEMENT, LLC 1.74%
8Hood River Capital Management LLC 1.62%
9LORD, ABBETT & CO. LLC 1.49%
10Nuveen 1.14%

Reported KRYSTAL BIOTECH INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

KRYSTAL BIOTECH INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)4,341,447 15.22%Form 13F, quarter ended March 31, 2024
BlackRock3,834,128 13.44%Form 13F, quarter ended March 31, 2024
FMR LLC3,349,474 11.74%Proxy statement (DEF 14A), proxy filed April 4, 2024
Vanguard Group2,792,208 9.79%Form 13F, quarter ended March 31, 2024
Avoro Capital Advisors LLC2,565,555 8.99%Proxy statement (DEF 14A), proxy filed April 4, 2024
Krish S. Krishnan1,835,662 6.43%Proxy statement (DEF 14A), proxy filed April 4, 2024
Suma M. Krishnan1,755,332 6.15%Proxy statement (DEF 14A), proxy filed April 4, 2024
Redmile Group, LLC1,733,189 6.08%Proxy statement (DEF 14A), proxy filed April 4, 2024
State Street944,547 3.31%Form 13F, quarter ended March 31, 2024
T. Rowe Price658,618 2.31%Form 13F, quarter ended March 31, 2024

Percentages above are of 28,528,000 shares outstanding, as reported by KRYSTAL BIOTECH INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At KRYSTAL BIOTECH INC.'s shareholder meeting held May 17, 2024, in the 2023-2024 proxy season, 256 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,751 separate fund positions. On the most widely held item on that ballot — APPROVAL OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, ON A NON-BINDING… — KRYSTAL BIOTECH INC.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: KRYSTAL BIOTECH INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 21, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KRYSTAL BIOTECH INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

KRYSTAL BIOTECH INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “KRYSTAL BIOTECH (KRYS) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/krystal-biotech-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.